Tesaro (TSRO) PT Raised to $68 at Cantor Fitzgerald Following Strong SOLO1 Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TESARO Announces Data Presentations at ESMO 2018 Congress
October 20, 2018 1:30 AM EDTData presented indicate that TSR-042 (anti-PD-1 antibody) is well tolerated and has robust activity in patients with MSI-H endometrial cancerPRIMA safety data for individualized niraparib dose regimen presentedTop-line results for PRIMA trial of niraparib in first-line ovarian cancer regardless of biomarker status expected in late 2019
MUNICH, Germany, Oct. 20, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today summarized updated Phase 1 GARNET data of TSR-042 (anti-PD-1 antibody) in patients with recurrent or advanced microsatellite instability high... More
TESARO Announces Data Presentations at ESMO 2018 Congress
October 20, 2018 1:30 AM EDTData presented indicate that TSR-042 (anti-PD-1 antibody) is well tolerated and has robust activity in patients with MSI-H endometrial cancerPRIMA safety data for individualized niraparib dose regimen presentedTop-line results for PRIMA trial of niraparib in first-line ovarian cancer regardless of biomarker status expected in late 2019
MUNICH, Germany, Oct. 20, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today summarized updated Phase 1 GARNET data of TSR-042 (anti-PD-1 antibody) in patients with recurrent or advanced microsatellite instability high... More
TESARO to Announce Third-Quarter 2018 Financial Results on November 1, 2018
October 18, 2018 4:15 PM EDTWALTHAM, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO) will announce third-quarter 2018 financial results on Thursday, November 1, 2018, after the close of the U.S. financial markets. TESAROs senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on November 1, 2018 to discuss the... More
TESARO to Announce Third-Quarter 2018 Financial Results on November 1, 2018
October 18, 2018 4:15 PM EDTWALTHAM, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO) will announce third-quarter 2018 financial results on Thursday, November 1, 2018, after the close of the U.S. financial markets. TESAROs senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on November 1, 2018 to... More
